Tumor Biology

, Volume 35, Issue 2, pp 1565–1574 | Cite as

RETRACTED ARTICLE: Prognostic and clinicopathological significance of survivin expression in bladder cancer patients: a meta-analysis

  • Shunzeng Lv
  • Ekaterina Turlova
  • Shigang Zhao
  • Huihui Kang
  • Mingzhi Han
  • Hong-Shuo Sun
Research Article


Survivin has been widely reported to play a role in diagnosis and prognosis of bladder cancer patients. However, published data on this subject are heterogeneous. Here, we conducted a meta-analysis to obtain a complete evaluation of the association between survivin and recurrence-free survival (RFS), disease-specific survival (DSS), overall survival (OS), and odds ratio (OR) in bladder cancer patients. Published studies on this subject were selected for further assessment by online articles in PubMed, MEDLINE, EMBASE, and OVID databases. Pooled hazard ratios (HR) with 95 % confidence interval (95 % CI) were estimated. Funnel plots were used to evaluate the publication bias. As well, heterogeneity and sensitivity were analyzed. In this meta-analysis, we included 13 studies with the total number of 1,963 patients. Positive survivin expression in bladder cancer was associated with a poor RFS (HR, 1.831; 95 % CI, 1.344–2.49), DSS (HR, 1.721; 95 % CI, 1.477–2.004), or OS (HR, 1.753; 95 % CI, 1.092–2.816) in patients. In addition, a significant association between expression of survivin and age (OR, 0.641; 95 % CI, 0.416–0.987) as well as stage (OR, 0.37; 95 % CI, 0.190–0.750) was revealed. Heterogeneity was observed among the included studies with RFS (x 2 = 29.58, p = 0.009, I 2 = 52.7 %), OS (x 2 = 15.67, p = 0.008, I 2 = 68.1 %), and stage (x 2 = 11.97, p = 0.035, I 2 = 58.2 %). There was no publication bias according to Begg’s and Egger’s tests except for studies with gender. Furthermore, sensitivity analysis obtained the source of heterogeneity and confirmed opposite results of some studies. This study suggests that expression of survivin indicates poor prognosis in older patients and muscle invasive or advanced stage in bladder cancer. Survivin expression could be used in identifying a subgroup of patients with potential to benefit from a targeted therapy against survivin.


Survivin Bladder cancer Prognosis Clinicopathology Meta-analysis 



This study was supported by China Scholarship Council. We were also very thankful to the support of Sun lab staff for their valuable advice.

Conflict of interest

The authors state that there are no conflicts of interest to disclose.


  1. 1.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E. Cancer statistics 2004. CA Cancer J Clin. 2004;54:8–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008;18:1–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett. 2006;244:164–71.CrossRefPubMedGoogle Scholar
  4. 4.
    Rödel F, Sprenger T, Kaina B, Liersch T, Rödel C, Fulda S, et al. Survivin as a prognostic/predictive marker and molecular target in cancer therapy. Curr Med Chem. 2012;19:3679–88.CrossRefPubMedGoogle Scholar
  5. 5.
    Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy. Expert Opin Ther Targets. 2008;12:463–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001;34:207–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Suzuki A, Ito T, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, et al. Survivin initiates procaspase-3/p21 complex formation as a result of interaction with CDK4 to resist Fas-mediated cell death. Oncogene. 2000;19:1346–51.CrossRefPubMedGoogle Scholar
  8. 8.
    Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7(e3):4100.Google Scholar
  9. 9.
    Li C, Li Z, Zhu M, Zhao T, Chen L, Ji W, et al. Clinicopathological and prognostic significance of survivin over-expression in patients with esophageal squamous cell carcinoma: a meta-analysis. PLoS One. 2012;7:e44764.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Li Y, Tan BB, Fan LQ, Zhao Q, Liu Y, Wang D. Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis. Hepatogastroenterology. 2010;57:1435–41.PubMedGoogle Scholar
  11. 11.
    Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 2007;67:5999–6002.CrossRefPubMedGoogle Scholar
  12. 12.
    Margulis V, Lotan Y, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer. BJU Int. 2008;102:15–22.CrossRefPubMedGoogle Scholar
  13. 13.
    Athanassiadou AM, Patsouris E, Tsipis A, Gonidi M, Athanassiadou P. The significance of Survivin and Nectin-4 ex-pression in the prognosis of breast carcinoma. Folia Histochem Cytobiol. 2011;49:26–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch. 2002;441(6):559–63.CrossRefPubMedGoogle Scholar
  15. 15.
    Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;8:705–19.CrossRefGoogle Scholar
  16. 16.
    Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7:8–16.Google Scholar
  17. 17.
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815–34.CrossRefPubMedGoogle Scholar
  18. 18.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, et al. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol. 2013;107(5):550–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Gradilone A, Petracca A, Nicolazzo C, Gianni W, Cortesi E, Naso G, et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 2010;106:710–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Weiss C, von Römer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, et al. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys. 2009;74(5):1455–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Ntinis A, et al. Survivin expression as a strong indicator of recurrence in urothelial bladder cancer. Anticancer Res. 2009;29:4163–7.PubMedGoogle Scholar
  23. 23.
    Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182:78–84.CrossRefPubMedGoogle Scholar
  24. 24.
    Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15:7012–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109:1106–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Pina-Cabral L, Santos L, Mesquita B, Amaro T, Magalhães S, Criado B. Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas. Clin Transl Oncol. 2007;9:731–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70:482–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8:128–36.CrossRefPubMedGoogle Scholar
  29. 29.
    Als AB, Dyrskjøt L, von der Maase H, Koed K, Mansilla F, Toldbod HE, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13:4407–14.CrossRefPubMedGoogle Scholar
  30. 30.
    Yin W, Chen N, Zhang Y, Zeng H, Chen X, He Y, et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol. 2006;19:1487–97.PubMedGoogle Scholar
  31. 31.
    Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A. 1988;151:419–63.CrossRefGoogle Scholar
  32. 32.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Shunzeng Lv
    • 1
  • Ekaterina Turlova
    • 1
  • Shigang Zhao
    • 2
  • Huihui Kang
    • 3
  • Mingzhi Han
    • 3
  • Hong-Shuo Sun
    • 1
  1. 1.Department of SurgeryUniversity of TorontoTorontoCanada
  2. 2.Department of MedicineShanghai Jiaotong UniversityShanghaiChina
  3. 3.Department of MedicineShandong UniversityJinan ShandongChina

Personalised recommendations